search for


Bleeding after Taking Dual Antiplatelets and NSAID Concurrently
Korean J Clin Pharm 2018;28(3):250-253
Published online September 30, 2018
© 2018 Korean College of Clinical Pharmacy.

Jeongmin Seo1, Joonghyuk Choi1, Pyoungwoo Son1, Seungmin Lee1, Hyunwoo Chae1, Geunhyung Kang2, and Eunhee Ji1,2,*

1College of Pharmacy, Gachon University, Incheon 21936, Republic of Korea,
2Center for Drug and Food Safety, Incheon Pharmaceutical Association, Incheon 22218, Republic of Korea
Correspondence to: Eunhee Ji, College of Pharmacy, Gachon University, 199 Hambakmoe-ro, Yeonsu-gu, Incheon 21936, Republic of Korea Tel: +82-32-820-4939, Fax: +82-32-820-4829 E-mail:
Received July 10, 2018; Revised September 3, 2018; Accepted September 4, 2018.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

When stenting is applied to treat myocardial infarction, antiplatelet agents are administered to prevent thrombosis, which increases the risk of bleeding. Patients with myocardial infarction are also more likely to have osteoarthritis simultaneously, because both diseases occur frequently in elderly patients. Patients with osteoarthritis often use analgesics, especially nonsteroidal antiinflammatory drugs (NSAIDs); hence, patients with both diseases use analgesics and antiplatelet agents simultaneously. The risk of bleeding increases with the use of antiplatelet agents and this is further increased when NSAIDs are added. We would like to report a case that reflects this situation. A 60-year-old man underwent stenting after ST-elevation myocardial infarction, and was treated with aspirin and clopidogrel. This patient also received a pelubiprofen prescription from another physician to treat osteoarthritis. After the patient took pelubiprofen twice, he found a bruise on his wrist and reported it to the pharmacist. It is unlikely that this is rare in community pharmacies, so pharmacists should pay careful attention to the concomitant administration of analgesics to patients receiving antiplatelet agents and should provide appropriate education to patients.

Keywords : Bleeding, antiplatelet agents, NSAIDs, stenting, osteoarthritis
증례 보고
감사의 말씀
  1. Wu C, Camacho FT, and Zhao S et al. Long-term mortality of coronary artery bypass graft surgery and stenting with drug-eluting stents. Ann Thorac Surg 2013;95:1297-305.
    Pubmed KoreaMed CrossRef
  2. Levine GN, Bates ER, and Bittl JA et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease:a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2016;68:1082-115.
    Pubmed CrossRef
  3. Andell P, James SK, and Cannon CP et al. Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease:An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial. J Am Heart Assoc 2015;4:e002490.
    Pubmed KoreaMed CrossRef
  4. Hochberg MC, Altman RD, and April KT et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res 2012;64:465-74.
  5. Korean Knee Sciety. Guidelines for the management of postoperative pain after total knee arthroplasty. Knee Surg Relat Res 2012;24:201-7.
    Pubmed KoreaMed CrossRef
  6. Managing Postoperative Pain, Swelling, and Bruising After Total Knee Replacement. Available from Accessed April 20, 2018
  7. Korea Centers for Disease Control & Prevention. Epidemiology and Management of Cardio-cerebrovascular Disease for Preventive Management of Community Cardio-cerebrovascular Disease 2013:518.
  8. Mauri L, Kereiakes DJ, and Yeh RW et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. Engl J Med 2014;371:2155-66.
    Pubmed KoreaMed CrossRef
  9. He F, Xia C, and Zhang JH et al. Clopidogrel plus aspirin versus aspirin alone for preventing early neurological deterioration in patients with acute ischemic stroke. J Clin Neurosci 2015;22:83-6.
    Pubmed CrossRef
  10. Liu Y, Liu H, and Hao Y et al. Short-term efficacy and safety of three different antiplatelet regimens in diabetic patients treated with primary percutaneous coronary intervention:a randomised study. Kardiol Pol 2017;75:850-8.
    Pubmed CrossRef
  11. van Hecken A, Depre M, and Wynants K et al. Effect of clopidogrel on naproxen-induced gastrointestinal blood loss in healthy volunteers. Drug Metabol Drug Interact 1998;14:193-205.
  12. Liu L, Wong KS, and Leng X et al. Dual antiplatelet therapy in stroke and ICAS:Subgroup analysis of CHANCE. Neurology 2015;85:1154-62.
    Pubmed KoreaMed CrossRef
  13. Schafer AI. Effects of nonsteroidal antiinflammatory drugs on platelet function and systemic hemostasis. J Clin Pharmacol 1995;35:209-19.
    Pubmed CrossRef
  14. Meek IL, Van de Laar MA, and H EV. Non-Steroidal Anti-Inflammatory Drugs:An Overview of Cardiovascular Risks. Pharmaceuticals (Basel) 2010;3:2146-62.
    Pubmed KoreaMed CrossRef
  15. Schror K. Aspirin and platelets:the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost 1997;23:349-56.
    Pubmed CrossRef
  16. Warner TD, Nylander S, and Whatling C. Anti-platelet therapy:cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy. Br J Clin Pharmacol 2011;72:619-33.
    Pubmed KoreaMed CrossRef

December 2018, 28 (4)
Full Text(PDF) Free

Social Network Service

Cited By Articles
  • CrossRef (0)

Funding Information
  • Incheon Pharmaceutical Association